<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2022</study_start_year><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><condition>Cancer</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><disease>Cancer</disease><study_type>Observational</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2404245</full_dataset_link><location>United States</location><study_start_month>6</study_start_month><keyword>Observational</keyword><keyword>Precision medicine</keyword><keyword>CRC</keyword><keyword>Genomic Profiling</keyword><keyword>Biomarkers</keyword><keyword>Oncology</keyword><keyword>NGS</keyword><repository>ECRIN MDR</repository><study_status>Recruiting</study_status></additional><is_claimable>false</is_claimable><name>Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays</name><description>The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.</description><dates><creation>2022-06-15</creation></dates><accession>2404245</accession><cross_references><ClinicalTrials___gov>NCT05234177</ClinicalTrials___gov></cross_references></HashMap>